DoseMe Expands Leadership Team with Appointments of Paul Edwards to CEO, John Hardesky to CCO and Sharmeen Roy to Chief Strategy & Science Officer
In this article:
Company adds expertise to support industry alignment with federal regulations and current recommendations from scientific and professional organizations
DoseMe, a leading provider of precision dosing software for therapeutic drug monitoring and creators of DoseMeRx and DoseMe Analytics, today announced the appointments of Paul Edwards to Chief Executive Officer, John Hardesky to the role of Chief Commercial Officer and Dr. Sharmeen Roy, PharmD, BCPS, to Chief Strategy and Science Officer.
This expansion of the senior leadership team will enable DoseMe to continue to evolve its precision dosing capabilities and ensure it is supporting hospitals and care teams to individualize patient treatment results.
Paul Edwards, CEO – Previously Paul held senior executive roles with Merck and GSK, as well as start-ups including ILUM Health Solutions, Infectious Disease Connect, and TrackMy Solutions. He has led strategic and operational teams that have implemented antimicrobial stewardship programs around the world, most notably in the United States, United Kingdom, India, South Africa, and Colombia.
John Hardesky, CCO – An accomplished senior leader with over 20 years of commercial experience focused on the global clinical market. He has been responsible for turnaround and growth results at a range of companies including Nanomix, Liquidsmarts, McKesson, and EliTech Group, where he launched over 20 product platforms to the global market.
Dr. Sharmeen Roy, PharmD, BCPS, CSSO – Passionate about leveraging technology to amplify the impact of the pharmacist, her career spans pediatric clinical pharmacy, clinical research, and pharmacogenomics with leadership roles at University of Chicago Medical Center and PipelineRx. She received her Doctor of Pharmacy degree from the University of Illinois at Chicago, is a Board Certified Pharmacotherapy Specialist and completed a Pediatric Specialty Pharmacotherapy Residency at Texas Children’s Hospital.
“The new combination of experience is designed to elevate the strategic counsel, product innovation and operations for both internal and external stakeholders,” said Paul Edwards, CEO of DoseMe. ”With an in-depth understanding of the demands of the industry, patient needs and technological advancements, we have an incredible opportunity to make a difference in healthcare.”
Bayesian dosing continues to draw more attention across the industry as there are at least 2.8 million antibiotic-resistant infections each year, and more than 35,000 people die as a result, according to the Centers for Disease Control and Prevention. DoseMe keeps its customers abreast of all changes and approaches to optimizing the use of antibiotics, with the core mission to maintain patient safety as the priority. Antibiotic stewardship programs play a critical role in supporting appropriate antibiotic prescribing practices and reducing antibiotic resistance.
As covered in a recent DoseMe blog, effective January 1, 2023, new and revised antibiotic stewardship requirements will apply to all Joint Commission–accredited hospitals and critical access hospitals. The 12 elements of performance (EPs) are included in the “Medication Management” (MM) chapter and expand upon the current expectations for antibiotic stewardship programs in the hospital setting.
DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA, ISO & FDA compliant and the only Bayesian dosing platform to be HITRUST CSF certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit https://doseme-rx.com/success-stories